Alza Corp. (ASE:AZA) of Palo Alto, Calif., announced severalorganizational changes, including senior managementpromotions.

The company's research and development activities have beenreorganized around product development units under Dr. FelixTheeuwes, the company's chief scientist, who has beenpromoted to executive vice president.

Named executive directors of the individual productdevelopment units are: Dr. Terry Burkoth, parenteral products;J. Benjamin Eckenhoff, veterinary products; Dr. David Enscore,oral cavity products; Dr. Ron Haak, electrotransport products;and Dr. David Swanson and Dr. Pat Wong, oral products.

Alza also said that Harold Fethe, senior director of humanresources since 1988, has been promoted to vice president ofhuman resources.

Dr. Antonie T. Knoppers has been elected to the board ofAgouron Pharmaceuticals Inc. (NASDAQ:AGPH), a La Jolla,Calif., developer of drugs for the treatment of cancer, AIDS andinfectious diseases. Knoppers is former president, chiefexecutive officer and vice chairman of Merck & Co. Inc.

Agouron also appointed R. Kent Snyder vice president ofbusiness development. Snyder had been director ofU.S./European licensing at Marion Merrell Dow Inc.

Agouron also appointed Praveen Tyle, Ph.D., director ofpharmaceutical development. Tyle had held productdevelopment positions at Sandoz Pharmaceuticals Corp. andAmerican Cyanamid Co.

Dr. James N. Woody has been named a senior vice president ofCentocor Inc. (NASDAQ:CNTO) of Malvern, Pa., effective Aug. 1,following his retirement from the U.S. Navy, where he servedas commanding officer of the Naval Medical Research andDevelopment Command. Woody will be responsible for managingCentocor's research and development staff. The companydevelops diagnostics and therapeutics for human health care.

Chiron Corp. (NASDAQ:CHIR) of Emeryville, Calif., has electedLewis W. Coleman, vice president and head of the WorldBanking Group of the Bank of America, to its board ofdirectors.

(c) 1997 American Health Consultants. All rights reserved.